Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
← catalyst calendarNCT06824168 · readout in 657 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
130estimated
Sites
58
Countries
Australia, Brazil, China +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-18 | actual | When the study began enrolling |
| Primary completion | 2028-06-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-07-14 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute Myeloid Leukemia
- Leukemia
Interventions
- Drug: Quizartinib High Dose — also filed as VANFLYTA®
- Drug: Quizartinib Low Dose — also filed as VANFLYTA®
Primary outcome
what the primary-completion date above is the date OFSerious Treatment Emergent Adverse Events (TEAEs)
measured From date of first dose to 30 days after last dose, up to 87 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed